Antibiotics for treatment of resistant gram-positive coccal infections.
Vancomycin is considered the workhorse for the treatment of most drug-resistant gram-positive bacterial infections. However, concerns have been raised regarding the increasing rates of vancomycin-resistant enterococci and the clinical shortcomings of vancomycin in the treatment of invasive Staphylococcus aureus infections. Resources have been committed to the development of antimicrobial agents with activity against these organisms. This review will focus on the newer antibacterial agents that have been developed for the treatment of resistant gram-positive pathogens. Included in this review are the agents: quinupristin-dalfopristin, linezolid, daptomycin, telithromycin, and tigecycline.
Al-Tatari
Hossam
H
Division of Infectious Diseases, Children's Hospital of Michigan; Carman and Ann Adams, Department of Pediatrics, Wayne State University School of Medicine, Detroit 48201, USA.
Abdel-Haq
Nahed
N
Chearskul
Pimpanada
P
Asmar
Basim
B
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D048628:Ketolides / Q000627:therapeutic use; D008911:Minocycline / Q000031:analogs & derivatives / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D048628:Ketolides; D010456:Peptides, Cyclic; D000078304:Tigecycline; D008911:Minocycline; C106791:telithromycin